LB Pharmaceuticals Inc (LBRX) is a clinical-stage pharma company with a single product candidate, LB-102, in Phase 3 development for schizophrenia. Under a liquidation lens as of March 31, 2026, equity recovery is positive and material, driven almost entirely by liquid financial assets. Total assets are $393.5M against total liabilities of $14.8M, yielding reported book equity of $378.7M. The MFFAIS CLV/LLV/OLV are each stated at $303.6M, which applies conservative haircuts or adjustments relative to book. Under standard liquidation haircuts: cash and equivalents of $320.7M recover at 100% ($320.7M); short-term marketable securities of $45.0M (investment-grade debt securities with $208K unrealized gain) recover at approximately 97-100% given mark-to-market carrying value (~$44.9M-$45.0M); prepaid and other current assets of $23.4M recover at approximately 0-10% (mostly clinical trial prepaid advances to CROs, not recoverable in a wind-down); PP&E net of $1.5M recovers at perhaps 30-50% ($0.5M-$0.8M); operating lease ROU asset of $2.1M recovers at 0% (intangible in nature). Against face-value liabilities: current liabilities of $10.9M (AP $7.1M, accrued liabilities $3.1M, current portion of lease $0.7M, derivative $1.1M, restructuring $0.3M) and noncurrent liabilities of $3.9M (operating lease $2.7M, derivative $1.1M). Total liability face-value stack is approximately $14.8M. Estimated liquidation recovery to equity: roughly $320.7M + $44.9M + $0 (prepaid) + $0.6M (PP&E) - $14.8M = approximately $351.4M, or somewhat less after winding up costs. This is a positively-valued liquidation estate, which is unusual and reflects the September 2025 IPO gross proceeds of $327.75M (net ~$302.3M) and a February 2026 private placement raising gross $100M. The company IPO'd in September 2025 and is a recent public company. Material weaknesses in internal controls over financial reporting were identified as of December 31, 2025 and disclosed in the current filing risk factors; remediation status as of March 31, 2026 is not separately confirmed in the filing body provided. Royalty obligations of up to 2.75%-3.25% of LB-102 net sales are off-balance-sheet contingent liabilities that do not appear in the liability stack but would reduce equity value in any commercialization scenario; they do not affect liquidation value since no sales exist. Off-balance-sheet CRO funding commitments of approximately $27.7M disclosed in the December 31, 2025 10-K (prior filing) represent contingent outflows that are generally terminable; no equivalent figure is separately tagged or disclosed in the current 10-Q period balance sheet. The filing discusses prepaid CRO advances totaling $23.4M in current prepaid assets but does not separately tag individual CRO advance amounts in XBRL for the Q1 2026 period.
▼ Community Notes